Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Salvage radiation therapy (SRT) and surveillance for low-risk prostate-specific antigen (PSA) recurrence have competing risks and benefits. The efficacy of early SRT to the prostate bed with or without pelvic lymph nodes compared to surveillance in patients with PSA recurrence after radical prostatectomy and no identifiable recurrent disease evident on prostate specific membrane antigen-positron emission tomography/computer tomography (PSMA-PET/CT) is unknown.
Study Design: The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) is an open-label, multicentre, randomised Phase II trial.
Endpoints: The primary endpoint is 3-year event-free survival, with events comprising one of PSA recurrence (PSA ≥0.2 ng/mL higher than baseline), radiological evidence of metastatic disease, or initiation of systemic or other salvage treatments. Secondary endpoints include patient-reported outcomes, treatment patterns, participant perceptions, and cost-effectiveness.
Eligibility Criteria: Eligible participants have PSA recurrence of prostate cancer after radical prostatectomy, defined by serum PSA level of 0.2-0.5 ng/mL, deemed low risk according to modified European Association of Urology biochemical recurrence risk criteria (International Society for Urological Pathology Grade Group ≤2, PSA doubling time >12 months), with no definite/probable recurrent prostate cancer on PSMA-PET/CT.
Patients And Methods: A total of 100 participants will be recruited from five Australian centres and randomised 1:1 to SRT or surveillance. Participants will undergo 6-monthly clinical evaluation for up to 36 months. Androgen-deprivation therapy is not permissible. Enrolment commenced May 2023.
Trial Registration: This trial has been registered with the Australian New Zealand Clinical Trials Registry (ACTRN: ACTRN12622001478707).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bju.16158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of robot-assisted radical prostatectomy with novel robotic platforms vs da Vinci multiport systems: a systematic review and network meta-analysis.
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
Introduction: The introduction of novel robotic platforms has expanded surgical options for robot-assisted radical prostatectomy (RARP). However, comparative outcomes with da Vinci multiport (MP) system remain unclear. This systematic review and network meta-analysis aimed to compare perioperative, early oncological, and functional outcomes of RARP performed with novel robotic platforms versus the da Vinci MP system.
View Article and Find Full Text PDFDiagnostic performance of Ga-PSMA-11 PET/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram.
Urol Oncol
September 2025
Faculty of Medicine, Department of Nuclear Medicine, Gazi University, Beşevler Ankara, Turkey.
Background: This study aimed to evaluate the diagnostic performance of Ga-PSMA-11 PET/MRI in prostate cancer (PC) with biochemical recurrence (BCR) after radical prostatectomy (RP). It was also aimed to develop a nomogram to predict PET/MRI positivity.
Methods: The data of 140 PC patients who underwent Ga-PSMA-11 PET/MRI for BCR after RP were retrospectively analyzed.
Simple prostatectomy followed by radiation therapy for prostate cancer: a novel treatment pathway for men with marked prostatomegaly and prostate cancer: a series of cases.
Can J Urol
August 2025
Department of Urology, Duke University Hospital, Durham, NC 27710, USA.
Background: Radical prostatectomy has long been the treatment of choice for men with clinically significant prostate cancer (PCa) in those with concurrent significant lower urinary tract symptoms (LUTS). For men who meet this description with marked prostatomegaly, we present a multi-institutional proof of concept study describing an alternative pathway of robotic simple prostatectomy (RASP) followed by external beam radiation therapy (EBRT) for the treatment of clinically significant prostate cancer.
Methods: A retrospective study was performed of 17 patients with PCa who underwent RASP followed by EBRT at two institutions from 2015-2023.
A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer.
IJU Case Rep
September 2025
Department of Urology, Faculty of Medicine, Saga University, Saga, Japan.
Introduction: We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.
Case Presentation: A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL.
Purpose: Perineural invasion (PNI) and lymphovascular invasion (LVI) represent tumor escape mechanisms at radical prostatectomy (RP). We assessed their prognostic significance for biochemical recurrence (BCR) following complete resection.
Methods: We analyzed 10,471 men with negative surgical margins after RP, stratified into three groups based on pathological PNI and LVI status: Group 1 (PNI-/LVI-, n = 1,925), Group 2 (PNI+/LVI-, n = 7,849), and Group 3 (LVI+, n = 697; 14 with PNI-/LVI + and 683 with PNI+/LVI+).